Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Beta-blocker treatment"'
Autor:
Anna Meta Dyrvig Kristensen, Ann Bovin, Ann Dorthe Zwisler, Charlotte Cerquira, Christian Torp-Pedersen, Hans Erik Bøtker, Ida Gustafsson, Karsten Tange Veien, Kristian Korsgaard Thomsen, Michael Hecht Olsen, Mogens Lytken Larsen, Olav Wendelboe Nielsen, Per Hildebrandt, Sussie Foghmar, Svend Eggert Jensen, Theis Lange, Thomas Sehested, Tomas Jernberg, Dan Atar, Borja Ibanez, Eva Prescott
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Treatment with beta-blockers is currently recommended after myocardial infarction (MI). The evidence relies on trials conducted decades ago before implementation of revascularization and contemporary medical therapy or in trials e
Externí odkaz:
https://doaj.org/article/b2a595e6a6e1488cb7c02796601af971
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Türk Kardiyoloji Derneği Arşivi, Vol 44, Iss 2, Pp 161-165 (2016)
Takotsubo cardiomyopathy (TCM) is an unusual form of acute cardiomyopathy showing left ventricular apical ballooning. Patients with hypotension should undergo urgent echocardiography to determine if left ventricular outflow tract (LVOT) obstruction i
Externí odkaz:
https://doaj.org/article/c620bd3460aa46fb85e772ee694320cb
Autor:
Lindgren, Arvid
Background: Surgical stress during resection surgery for colon cancer has previously been shown to be associated with adverse postoperative outcomes. Statin and beta-blocker treatment have been shown to lower postoperative complications and mortality
Externí odkaz:
http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-103515
Autor:
Masashi Mizokami, Jin Takasaki, Masayuki Hojo, Noriko Kinoshita, Haruhito Sugiyama, Sho Saito, Masaya Sugiyama, Satoshi Kutsuna, Hidetoshi Nomoto, Masahiro Ishikane, Masao Hashimoto, Shinyu Izumi, Kayoko Hayakawa, Toshikazu Kano, Manabu Suzuki, Nao Nishida, Hiroyuki Gatanaga, Norio Ohmagari, Kiyoto Tsuchiya, Takato Nakamoto, Tatsuya Kanto, Hidekatsu Yanai, Satoshi Ide, Masahide Usami
Publikováno v:
Gene
Highlights • CCL17, IFN- l 3, IL-6, IP-10, and CXCL9 were predictor for COVID-19 prognosis. • CCL17 were showed strong association with the development of severe pneumonia. • A flare-up of IFN- l 3, IL-6, IP-10, and CXCL9 were a trigger for sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d479f193aed7da1d3ecdc3387cf9b08
https://pubmed.ncbi.nlm.nih.gov/33289211
https://pubmed.ncbi.nlm.nih.gov/33289211
Autor:
Sussie Foghmar, Kristian Korsgaard Thomsen, Karsten Tange Veien, Tomas Jernberg, Christian Torp-Pedersen, Thomas S. G. Sehested, Eva Prescott, Per Hildebrandt, Anna Meta Dyrvig Kristensen, Borja Ibanez, Ann-Dorthe Zwisler, Ann Bovin, Hans Erik Bøtker, Theis Lange, Ida Gustafsson, Svend Eggert Jensen, Michael H. Olsen, Mogens Lytken Larsen, Charlotte Cerquira, Olav W. Nielsen, Dan Atar
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-11 (2020)
Kristensen, A M D, Bovin, A, Zwisler, A D, Cerquira, C, Torp-Pedersen, C, Bøtker, H E, Gustafsson, I, Veien, K T, Thomsen, K K, Olsen, M H, Larsen, M L, Nielsen, O W, Hildebrandt, P, Foghmar, S, Jensen, S E, Lange, T, Sehested, T, Jernberg, T, Atar, D, Ibanez, B & Prescott, E 2020, ' Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction : Study protocol for a randomized controlled trial ', Trials, vol. 21, no. 1, 415 . https://doi.org/10.1186/s13063-020-4214-6
Repisalud
Instituto de Salud Carlos III (ISCIII)
Trials
Kristensen, A M D, Bovin, A, Zwisler, A D, Cerquira, C, Torp-Pedersen, C, Bøtker, H E, Gustafsson, I, Veien, K T, Thomsen, K K, Olsen, M H, Larsen, M L, Nielsen, O W, Hildebrandt, P, Foghmar, S, Jensen, S E, Lange, T, Sehested, T, Jernberg, T, Atar, D, Ibanez, B & Prescott, E 2020, ' Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction : Study protocol for a randomized controlled trial ', Trials, vol. 21, 415 . https://doi.org/10.1186/s13063-020-4214-6
Kristensen, A M D, Bovin, A, Zwisler, A D, Cerquira, C, Torp-Pedersen, C, Bøtker, H E, Gustafsson, I, Veien, K T, Thomsen, K K, Olsen, M H, Larsen, M L, Nielsen, O W, Hildebrandt, P, Foghmar, S, Jensen, S E, Lange, T, Sehested, T, Jernberg, T, Atar, D, Ibanez, B & Prescott, E 2020, ' Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction : Study protocol for a randomized controlled trial ', Trials, vol. 21, no. 1, 415 . https://doi.org/10.1186/s13063-020-4214-6
Repisalud
Instituto de Salud Carlos III (ISCIII)
Trials
Kristensen, A M D, Bovin, A, Zwisler, A D, Cerquira, C, Torp-Pedersen, C, Bøtker, H E, Gustafsson, I, Veien, K T, Thomsen, K K, Olsen, M H, Larsen, M L, Nielsen, O W, Hildebrandt, P, Foghmar, S, Jensen, S E, Lange, T, Sehested, T, Jernberg, T, Atar, D, Ibanez, B & Prescott, E 2020, ' Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction : Study protocol for a randomized controlled trial ', Trials, vol. 21, 415 . https://doi.org/10.1186/s13063-020-4214-6
BackgroundTreatment with beta-blockers is currently recommended after myocardial infarction (MI). The evidence relies on trials conducted decades ago before implementation of revascularization and contemporary medical therapy or in trials enrolling p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9398f1a668d3def37b9b338c863c324
https://hdl.handle.net/20.500.12105/10356
https://hdl.handle.net/20.500.12105/10356
Autor:
Imran Onur, Mehmet Rasih-Sonsoz, Ahmet Kaya Bilge, Kamil Gulsen, Hasan Ali-Barman, Adem Atici, Ali Elitok, Ahmet Demirkiran, Eser Durmaz, Irfan Sahin
espanolAntecedentes: el sincope vasovagal (VVS) es una condicion clinica comun que involucra antecedentes geneticos. El papel de los betabloqueantes en el tratamiento es controvertido. Objetivo: El objetivo de este estudio fue investigar el efecto de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc3f766cbf7f750beea1b2a4f8ba1f52
https://hdl.handle.net/20.500.12831/6312
https://hdl.handle.net/20.500.12831/6312
Autor:
William H. Sauer, Hussein R. Al-Khalidi, Dirk J. van Veldhuisen, Gordon Davis, Richard Clark, William T. Abraham, Patricia Dignacco, Stephen B. Wilton, Christopher Dufton, Ryan G. Aleong, Benjamin A. Steinberg, Debra Marshall, Michael R. Bristow, Laura L. Emery, Stuart J. Connolly, Michel White, Jonathan P. Piccini, Inder S. Anand, Jeff S. Healey
Publikováno v:
American Heart Journal, 199, 51-58. MOSBY-ELSEVIER
Background Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d164044278b9a2064489078877018f8
https://research.rug.nl/en/publications/b8f34bcf-6be6-4acc-80b3-4d767404c8c2
https://research.rug.nl/en/publications/b8f34bcf-6be6-4acc-80b3-4d767404c8c2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.